Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel

Castration-resistant prostate cancer (CRPC) represents the final stage of prostate cancer (PCa).

Cabazitaxel, a taxane chemotherapy drug, is used in treating CRPC.

However, patients with CRPC eventually develop resistance to cabazitaxel, and the underlying mechanism remains unclear.

Here, we aimed to investigate potential genetic alterations that may play a role in CRPC resistance to cabazitaxel.

Using microarray data from the GSE158494 dataset, we identified ten critical genes ( CXCL8 , ITGB8 , CLIP4 , MAP1B , WIPI1 , MMP13 , CXCL1 , C1S , GOLGA8B , and CXCL6 ) associated with CRPC cell resistance to cabazitaxel.

The potential function of these key genes in PCa progression was analyzed using different databases, including Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA).

Our findings revealed altered expression of these genes in the development of PCa.

Furthermore, CXCL1 and GOLGA8B were found to influence the disease-free survival (DFS) status of patients with PCa, with GOLGA8B affecting the overall prognosis in patients with PCa.

Additionally, GOLGA8B expression was associated with the infiltration of various immune cells in PCa, and it was upregulated in clinical PCa and CRPC samples.

Through CCK-8 assays, we established that GOLGA8B could influence the sensitivity of CRPC cells to cabazitaxel and docetaxel.

In conclusion, we identified GOLGA8B as a crucial gene that influences PCa progression and contributes to CRPC resistance to cabazitaxel.